SCHEMBL3757595

SCHEMBL3757595

S=c1nc(Cc2ccccc2)[nH]c2nc[nH]c12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
HPGD P15428 3/20 0.50
ADORA3 P0DMS8 2/20 0.50
TP53 P04637 2/20 0.50
PTGS1 P23219 2/20 0.50
HBB P68871 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
USP2 O75604 1/20 0.50
MAPK3 P27361 1/20 0.50
XDH P47989 1/20 0.50
PAX8 Q06710 1/20 0.50
POLA1 P09884 1/20 0.43
GAA P10253 2/20 0.43
ADORA2B P29275 1/20 0.43
PDE4A P27815 1/20 0.43
PDE4B Q07343 1/20 0.43
PDE4C Q08493 1/20 0.43
PDE4D Q08499 1/20 0.43
TDP1 Q9NUW8 2/20 0.42
KDM4E B2RXH2 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28817761 0.82 ADORA3 (0.49) ADORA3GAAADORA2BPDE4APDE4B
SCHEMBL3757599 0.77 PDE4A (0.49) ALDH1A1HPGDADORA3GAAPDE4A
SCHEMBL7977497 0.75 ADORA3 (0.42) ALDH1A1HPGDADORA3GAAADORA2B
SCHEMBL31487265 0.72 RIPK1 (0.47) ALDH1A1GAAPRNPMAPTKMT2A
SCHEMBL11135475 0.71 ALDH1A1 (0.62) ALDH1A1HPGDADORA3TP53PTGS1
SCHEMBL5088503 0.71 PNP (0.48) ADORA3GAAADORA2BTAAR1KMT2A
SCHEMBL5084818 0.71 PNP (0.58) PDE4APDE4BPDE4CPDE4DKMT2A
SCHEMBL7120142 0.69 ADORA3 (0.39) ADORA3SMN1; SMN2ADORA2BMAPTTAAR1
Thioguanine SCHEMBL31327802 0.67 ALDH1A1 (1.00) ALDH1A1HPGDADORA3TP53PTGS1
Thioguanine SCHEMBL28134237 0.67 ALDH1A1 (1.00) ALDH1A1HPGDADORA3TP53PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680270-B2 Metallo-oxidoreductase inhibitors using metal binding moieties in combination with targeting moieties VIAMET PHARMACEUTICALS, INC. (US) 2014-03-25 US disclosed
EP-2086546-B1 METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES VIAMET PHARMACEUTICALS INC (US) 2013-07-10 EP disclosed
US-20100305078-A1 METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES VIAMET PHARMACEUTICALS, INC. (US) 2010-12-02 US disclosed
EP-2086546-A2 METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES Viamet Pharmaceuticals, Inc. (US) 2009-08-12 EP disclosed
WO-2008064311-A2 METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES VIAMET PHARMACEUTICALS, INC. (US) 2008-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305078-A1 METALLO-OXIDOREDUCTASE INHIBITORS USING METAL BINDING MOIETIES IN COMBINATION WITH TARGETING MOIETIES NQO1, SOD1, MDH2 ALDH1A1 406/4885HPGD 178/4885ADORA3 4809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.